- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI)
- Interventions
- Florbetapir, Flortaucipir
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1,182 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced May 22, 2026, 1:12 AM EDT